Browne L Daniel Form 4 August 25, 2017

## FORM 4

#### OMB APPROVAL

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Check this box if no longer subject to Section 16. Form 4 or Expires: January 31,

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per response... 0.5

Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Browne L Daniel			2. Issuer Name <b>and</b> Ticker or Trading Symbol Revance Therapeutics, Inc. [RVNC]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
(Last)	(Last) (First) (Middle)		3. Date of Earliest Transaction	( and approximate)			
C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD			(Month/Day/Year) 08/23/2017	_X_ Director 10% Owner X Officer (give title Other (specify below) CEO and President			
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
NEWARK, C	CA 94560		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			

(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
--------	---------	-------	--

						•	, . ,		·
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit for Dispos (Instr. 3,	ed of	` '	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	(IIIsu. +)
Common Stock	08/23/2017		M	331	A	\$ 2.55	178,850	D	
Common Stock	08/23/2017		S <u>(1)</u>	22,800	D	\$ 22.7645 (2)	156,050	D	
Common Stock							409	I	See footnote (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: Browne L Daniel - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secur (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 2.55	08/23/2017		M	331	<u>(4)</u>	07/20/2020	Common Stock	331	\$

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
- G	Director	10% Owner	Officer	Other		
Browne L Daniel						
C/O REVANCE THERAPEUTICS, INC.	X		CEO and Dragidant			
7555 GATEWAY BOULEVARD	Λ		CEO and President			
NEWARK CA 94560						

## **Signatures**

/s/ Gordon Ho,
Attorney-in-Fact

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging (2) from \$22.50 to \$23.20. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Reporting Owners 2

#### Edgar Filing: Browne L Daniel - Form 4

- (3) These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
- (4) The Option is fully vested as of January 1, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.